ICUI
ICU Medical, Inc. · Healthcare · Medical - Instruments & Supplies
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 0 | 16.66M | $2.44B | +7 | −6 |
| Q1 2026 | 104 | -4 | 18.58M | $2.40B | +5 | −10 |
| Q4 2025 | 108 | +2 | 19.90M | $2.83B | +3 | — |
| Q3 2025 | 19 | +2 | 11.89M | $1.43B | +3 | −2 |
| Q2 2025 | 15 | -1 | 9.62M | $1.27B | — | −1 |
| Q1 2025 | 13 | +1 | 2.74M | $379.97M | +2 | −1 |
| Q4 2024 | 12 | 0 | 3.47M | $538.76M | — | — |
| Q3 2024 | 11 | -2 | 3.16M | $575.79M | — | −2 |
| Q2 2024 | 13 | — | 2.88M | $341.58M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.44M | — | $171.33M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 498.85K | — | $59.25M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 498.85K | — | $59.25M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 281.88K | — | $33.47M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 205.83K | — | $24.44M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Norges Bank ✦ (passive) | 204.59K | — | $24.29M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Millennium Management ✦ | 136.07K | — | $16.16M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 28.63K | — | $3.40M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 28.63K | — | $3.40M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 28.63K | — | $3.40M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 27.05K | — | $3.21M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 17.23K | — | $2.05M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 14.02K | — | $1.67M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 10.00K | — | $1.19M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 5.65K | — | $670,581 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Bridgewater Associates ✦ | 3.79K | — | $449,825 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 273 holders, 24.54M shares, $3.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 5.42K sh · $982,265
Officer · 2.25K sh · $401,209
Director · 378 sh · $68,978
Officer · 8.93K sh · $1.63M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology